Deutsche Bank Aktiengesellschaft Reaffirms "Hold" Rating for GSK (LON:GSK)

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Deutsche Bank Aktiengesellschaft restated their hold rating on shares of GSK (LON:GSK - Free Report) in a report released on Thursday, Marketbeat reports. Deutsche Bank Aktiengesellschaft currently has a GBX 1,450 ($19.27) price target on the stock.

Several other brokerages also recently commented on GSK. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a report on Friday, July 18th. Shore Capital restated a "buy" rating and set a GBX 2,000 ($26.58) price objective on shares of GSK in a research report on Wednesday, July 30th. Finally, Berenberg Bank restated a "hold" rating and set a GBX 1,600 ($21.27) price objective on shares of GSK in a research report on Friday, July 18th.

GSK Stock Performance

GSK traded up GBX 2 ($0.03) on Thursday, hitting GBX 1,398.50 ($18.59). The company's stock had a trading volume of 7,535,096 shares, compared to its average volume of 13,367,646. The company's 50 day simple moving average is GBX 1,434.66 and its 200-day simple moving average is GBX 1,426.66. The firm has a market cap of £56.75 billion, a P/E ratio of 22.59, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a 12 month low of GBX 1,242.50 ($16.51) and a 12 month high of GBX 1,678.68 ($22.31). The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported GBX 75.30 ($1.00) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Analysts forecast that GSK will post 175.980975 EPS for the current year.

Insider Activity

In related news, insider Emma Walmsley sold 5,473 shares of the business's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.26), for a total transaction of £79,303.77 ($105,401.08). Also, insider Jonathan Symonds bought 1,350 shares of the firm's stock in a transaction on Friday, June 20th. The stock was purchased at an average cost of GBX 1,435 ($19.07) per share, with a total value of £19,372.50 ($25,747.61). In the last 90 days, insiders have purchased 1,905 shares of company stock valued at $2,732,835. Corporate insiders own 1.61% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.